Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Appointed director
Quarterly results
Director departure
|
|
ANGIOTECH PHARMACEUTICALS INC (ANPMF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/28/2013 |
8-K
| Quarterly results |
| 03/19/2013 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 11/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2012 Vancouver, BC, November 14, 2012 — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the third quarter ended September 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on November 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “Our business performance in the third quarter continued to reflect exceptional efforts by our staff to turn our business around in 2012 and move it forward on a renewed path,” said Thomas Bailey, President and CEO of Angiotech. “Consistent with the first half of the year, we were able to continue our revenue growth, and our gross ..." |
|
| 09/20/2012 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 08/16/2012 |
8-K
| Credit agreement amendment|
Docs:
|
"Indenture, by and among Angiotech Pharmaceuticals (US), Inc., Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for 9% Senior Notes due 2016",
"Supplemental Indenture, by and among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for Senior Floating Rate Notes due 2013",
"Press Release" |
|
| 08/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2012 Vancouver, BC, — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the second quarter ended June 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on August 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “We are extremely pleased to announce our third consecutive quarter of significantly improved financial results. Our improved revenue growth, cash flows, liquidity and profitability are a culmination of the hard work and dedication of our team following the conclusion of our restructuring and business change initiatives last year,” said Thomas Bailey, Angiote..." |
|
| 05/15/2012 |
8-K
| Form 8-K - Current report |
| 04/10/2012 |
8-K
| Form 8-K - Current report |
| 03/16/2012 |
8-K
| Form 8-K - Current report |
| 11/09/2011 |
8-K
| Form 8-K - Current report |
| 10/21/2011 |
8-K
| Form 8-K - Current report |
| 08/09/2011 |
8-K
| Quarterly results |
| 07/20/2011 |
8-K
| Form 8-K - Current report |
| 07/15/2011 |
8-K
| Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen... |
| 05/16/2011 |
8-K
| Credit agreement amendment, Appointed a new director|
Docs:
|
"First Amendment to Notice of Articles of Angiotech Pharmaceuticals, Inc.",
"Second Amendment to Notice of Articles of Angiotech Pharmaceuticals, Inc.",
"Articles of Angiotech Pharmaceuticals, Inc",
"Indenture, by and among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for senior secured floating rate notes due 2013",
"Supplemental Indenture, by and among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for senior floating rate notes due 2013",
"Credit Agreement, by and among Angiotech Pharmaceuticals, Inc., as Parent, the subsidiaries of Parent listed as borrowers on the signature pages thereto, as borrowers, the lenders signatory thereto, as lenders and Wells Fargo Capital Finance, LLC as arranger and administrative agent",
"Registration Rights Agreement, among Angiotech Pharmaceuticals, Inc. and the investors party thereto",
"Angiotech Pharmaceuticals, Inc. 2011 Stock Incentive Plan",
"Form of Restricted Share Unit Award Agreement (for Canadian participants)",
"Form of Restricted Stock Award Agreement (for U.S. Participants)" |
|
| 05/16/2011 |
8-K
| Form 8-K - Current report |
| 04/29/2011 |
8-K
| Form 8-K - Current report |
| 04/25/2011 |
8-K
| Form 8-K - Current report |
| 04/11/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/06/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/05/2011 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/16/2011 |
8-K
| Quarterly results |
| 03/04/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/24/2011 |
8-K
| Form 8-K - Current report |
| 02/18/2011 |
8-K
| Form 8-K - Current report |
| 02/10/2011 |
8-K
| Form 8-K - Current report |
| 02/02/2011 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 02/01/2011 |
8-K
| Form 8-K - Current report |
| 01/28/2011 |
8-K
| Form 8-K - Current report |
| 01/12/2011 |
8-K
| Form 8-K - Current report |
| 01/06/2011 |
8-K
| Form 8-K - Current report |
| 01/06/2011 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 11/01/2010 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Recapitalization Support Agreement, among Angiotech Pharmaceuticals, Inc., and the holders of senior subordinated notes signatory thereto",
"Floating Rate Note Support Agreement, among Angiotech Pharmaceuticals, Inc., and the holders of floating rate notes signatory thereto",
"Supplemental Indenture, between Angiotech Pharmaceuticals, Inc. and U.S. Bank National Association, relating to the Company's 7.75% Subordinated Notes",
"Agreement and Plan of Merger, by and among the Company, Angiotech Pharmaceuticals (US), Inc., Quaich Acquisition, Inc. and Quill Medical, Inc",
"Angiotech Pharmaceuticals, Inc. Announces a Strongly Supported Transaction Agreement with Majority of Senior Subordinated Noteholders and Floating Rate Noteholders Vancouver, BC, October 29, 2010 - Angiotech Pharmaceuticals, Inc. today announced that the Company has entered into a Recapitalization Support Agreement with the holders of approximately 73% of its 7.75% Senior Subordinated Notes to effectuate a recapitalization of the Company that will result in a significant reduction of its debt. Upon implementation, the recapitalization transaction will eliminate $250 million in total indebtedness and provide significant improvements to Angiotech's credit ratios, liquidity and financial flexibility. “After a challenging period in our Company's financial history, we are now able to announce ...",
"Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information Vancouver, BC, October 29, 2010 - In September 2010, Angiotech Pharmaceuticals, Inc. entered into confidentiality, non-disclosure and non-use agreements with certain beneficial holders of and/or investment advisors with investment discretion over the Company's 7.75% Senior Subordinated Notes in order to facilitate discussion of a possible recapitalization transaction. Pursuant to the Confidentiality Agreements, Angiotech disclosed information, including certain non-public information , to such Subordinated Noteholders' financial and legal advisors. The Confidentiality Agreements require that Angiotech now disclose certain of the Non-Public Information. As previously announced on October 1, 2010, Angiotech de..." |
|
| 10/06/2010 |
8-K
| Form 8-K - Current report |
|
|
|